XML 30 R39.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)
9 Months Ended 12 Months Ended 24 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended
Sep. 30, 2013
Dec. 31, 2011
May 31, 2006
Oct. 31, 2004
Dec. 31, 2003
Series A Preferred Stock [Member]
Sep. 30, 2013
Series A Preferred Stock [Member]
Sep. 30, 2013
Series D Preferred Stock [Member]
Mar. 31, 2011
Series D Preferred Stock [Member]
Raven Biotechnologies Inc [Member]
Jul. 31, 2008
Series D Preferred Stock [Member]
Raven Biotechnologies Inc [Member]
Jan. 31, 2011
Series D Two Preferred Stock [Member]
May 30, 2010
Series D Two Preferred Stock [Member]
Sep. 30, 2008
Series D Two Preferred Stock [Member]
Sep. 30, 2013
Series D Two Preferred Stock [Member]
Sep. 30, 2013
Series A- One Preferred Stock [Member]
Sep. 30, 2013
Series A- Two Preferred Stock [Member]
Oct. 31, 2004
Series B Preferred Stock [Member]
Sep. 30, 2013
Series B Preferred Stock [Member]
May 31, 2006
Series C Preferred Stock [Member]
Sep. 30, 2013
Series C Preferred Stock [Member]
Stockholders Equity [Line Items]                                      
Number of shares issued or sold         34,239,374         18,427,388 6,916,110 38,337,678       71,401,237   110,952,217  
Proceeds from issuance of convertible preferred stock   $ 12,014,816     $ 34,000,000         $ 12,016,500   $ 24,843,211       $ 30,261,672   $ 44,898,754  
Convertible Preferred Stock Per Share         $ 1.00                            
Related offering costs                       156,788       238,000   101,246  
Shares of common stock allocated but unissued     10,003,300 13,604,016                              
Shares issued to acquire entity               14,446,227 12,466,039                    
Purchased shares                     518,708 2,875,327              
Exercise price                         0.65            
Outstanding stock 4,000,000                                    
Percentage of preferred stock holders with voting rights of board members 66.67%                                    
Accrued noncumulative dividends on preferred stock             $ 0.0522           $ 0.0522 $ 0.08 $ 0.08   $ 0.0341   $ 0.0324
Convertible preferred stock series             1.00           1.00 1.506 1.00   1.14   1.00
Conversion price of preferred stock             $ 12.20           $ 12.20 $ 12.39 $ 18.77   $ 6.95   $ 7.70
Reserved common stock 17,129,782                                    
Net proceeds from underwritten public offering upon closing of firm $ 40,000,000                                    
Earning per share received by the shareholders           $ 12.39 $ 12.20           $ 12.20       $ 6.95   $ 7.70
Reverse stock split 1-for-18.7739